Targeted Delivery System of Nanobiomaterials in Anticancer Therapy: From Cells to Clinics

被引:67
作者
Jin, Su-Eon [1 ]
Jin, Hyo-Eon [2 ,3 ]
Hong, Soon-Sun [1 ]
机构
[1] Inha Univ, Coll Med, Dept Drug Dev, Inchon 400712, South Korea
[2] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA
[3] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Phys Biosci Div, Berkeley, CA 94720 USA
基金
新加坡国家研究基金会;
关键词
IRON-OXIDE NANOPARTICLES; INCORPORATING MICELLAR NANOPARTICLE; PLGA-BASED NANOPARTICLES; DRUG-DELIVERY; IN-VIVO; PHASE-I; FOLATE RECEPTOR; BIOMEDICAL APPLICATIONS; GENE DELIVERY; LIPOSOMAL DOXORUBICIN;
D O I
10.1155/2014/814208
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Targeted delivery systems of nanobiomaterials are necessary to be developed for the diagnosis and treatment of cancer. Nanobiomaterials can be engineered to recognize cancer-specific receptors at the cellular levels and to deliver anticancer drugs into the diseased sites. In particular, nanobiomaterial-based nanocarriers, so-called nanoplatforms, are the design of the targeted delivery systems such as liposomes, polymeric nanoparticles/micelles, nanoconjugates, norganic materials, carbon-based nanobiomaterials, and bioinspired phage system, which are based on the nanosize of 1-100 nmin diameter. In this review, the design and the application of these nanoplatforms are discussed at the cellular levels as well as in the clinics. We believe that this review can offer recent advances in the targeted delivery systems of nanobiomaterials regarding in vitro and in vivo applications and the translation of nanobiomaterials to nanomedicine in anticancer therapy.
引用
收藏
页数:23
相关论文
共 206 条
[1]   Peptide-based targeting strategies for simultaneous imaging and therapy with nanovectors [J].
Accardo, Antonella ;
Tesauro, Diego ;
Morelli, Giancarlo .
POLYMER JOURNAL, 2013, 45 (05) :481-493
[2]   PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect [J].
Acharya, Sarbari ;
Sahoo, Sanjeeb K. .
ADVANCED DRUG DELIVERY REVIEWS, 2011, 63 (03) :170-183
[3]   Liposomes: From a Clinically Established Drug Delivery System to a Nanoparticle Platform for Theranostic Nanomedicine [J].
Al-Jamal, Wafa' T. ;
Kostarelos, Kostas .
ACCOUNTS OF CHEMICAL RESEARCH, 2011, 44 (10) :1094-1104
[4]   Effect of Doxorubicin/Pluronic SP1049C on Tumorigenicity, Aggressiveness, DNA Methylation and Stem Cell Markers in Murine Leukemia [J].
Alakhova, Daria Y. ;
Zhao, Yi ;
Li, Shu ;
Kabanov, Alexander V. .
PLOS ONE, 2013, 8 (08)
[5]   Drug delivery systems: Entering the mainstream [J].
Allen, TM ;
Cullis, PR .
SCIENCE, 2004, 303 (5665) :1818-1822
[6]  
Amin M., INT J PHARM, V458, P324
[7]  
[Anonymous], 2013, CANC FACTS FIG 2013
[8]   Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model [J].
Arap, W ;
Pasqualini, R ;
Ruoslahti, E .
SCIENCE, 1998, 279 (5349) :377-380
[9]   AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery [J].
Aravind, Athulya ;
Jeyamohan, Prashanti ;
Nair, Remya ;
Veeranarayanan, Srivani ;
Nagaoka, Yutaka ;
Yoshida, Yasuhiko ;
Maekawa, Toru ;
Kumar, D. Sakthi .
BIOTECHNOLOGY AND BIOENGINEERING, 2012, 109 (11) :2920-2931
[10]   Liposomes in drug delivery: a patent review (2007-present) [J].
Arias, Jose L. .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2013, 23 (11) :1399-1414